Avenge Bio
Biotechnology, 22 Strathmore Rd Ste 241, Natick, Massachusetts, 01760, United States, 11-50 Employees
Phone Number: 21********
Who is AVENGE BIO
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is d...
Read More
-
Headquarters: 22 Strathmore Rd Ste 241, Natick, Massachusetts, 01760, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from AVENGE BIO
Avenge Bio Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Avenge Bio
Answer: Avenge Bio's headquarters are located at 22 Strathmore Rd Ste 241, Natick, Massachusetts, 01760, United States
Answer: Avenge Bio's phone number is 21********
Answer: Avenge Bio's official website is https://avengebio.com
Answer: Avenge Bio's revenue is $1 Million to $5 Million
Answer: Avenge Bio's SIC: 8731
Answer: Avenge Bio has 11-50 employees
Answer: Avenge Bio is in Biotechnology
Answer: Avenge Bio contact info: Phone number: 21******** Website: https://avengebio.com
Answer: Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month